|
1
|
Hatzimichael E, Dasoula A, Benetatos L,
Syed N, Dranitsaris G, Crook T and Bourantas K: Study of specific
genetic and epigenetic variables in multiple myeloma. Leuk
Lymphoma. 51:2270–2274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson KC: Multiple myeloma: How far
have we come? Mayo Clin Proc. 78:15–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pichiorri F, Suh SS, Ladetto M, Kuehl M,
Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP,
Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI
and Croce CM: MicroRNAs regulate critical genes associated with
multiple myeloma pathogenesis. Proc Natl Acad Sci USA.
105:12885–12890. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Murphy T, Hori S, Sewell J and
Gnanapragasam VJ: Expression and functional role of negative
signalling regulators in tumour development and progression. Int J
Cancer. 127:2491–2499. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Edwin F, Anderson K, Ying C and Patel TB:
Intermolecular interactions of Sprouty proteins and their
implications in development and disease. Mol Pharmacol. 76:679–691.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feng YH, Wu CL, Shiau AL, Lee JC, Chang
JG, Lu PJ, Tung CL, Feng LY, Huang WT and Tsao CJ:
MicroRNA-21-mediated regulation of Sprouty2 protein expression
enhances the cytotoxic effect of 5-fluorouracil and metformin in
colon cancer cells. Int J Mol Med. 29:920–926. 2012.PubMed/NCBI
|
|
7
|
Lao DH, Chandramouli S, Yusoff P, Fong CW,
Saw TY, Tai LP, Yu CY, Leong HF and Guy GR: A Src homology
3-binding sequence on the C terminus of Sprouty2 is necessary for
inhibition of the Ras/ERK pathway downstream of fibroblast growth
factor receptor stimulation. J Biol Chem. 281:29993–30000. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sayed D, Rane S, Lypowy J, He M, Chen IY,
Vashistha H, Yan L, Malhotra A, Vatner D and Abdellatif M:
MicroRNA-21 targets Sprouty2 and promotes cellular out growths. Mol
Biol Cell. 19:3272–3282. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao
KQ, Livak KJ and Guegler KJ: Real-time quantification of microRNAs
by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C (T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar
|
|
11
|
Moriyama T, Ohuchida K, Mizumoto K, et al:
MicroRNA-21 modulates biological functions of pancreatic cancer
cells including their proliferation, invasion, and chemoresistance.
Mol Cancer Ther. 8:1067–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neri A, Giordano A, Munshi NC, Anderson
KC, Tagliaferri P and Tassone P: Targeting miR-21 inhibits in vitro
and in vivo multiple myeloma cell growth. Clin Cancer Res.
19:209–106. 2013.
|
|
13
|
Löffler D, Brocke-Heidrich K, Pfeifer G,
Stocsits C, Hackermüller J, Kretzschmar AK, Burger R, Gramatzki M,
Blumert C, Bauer K, Cvi jic H, Ullmann AK, Stadler PF and Horn F:
Interleukin-6 dependent survival of multiple myeloma cells involves
the Stat3-mediated induction of microRNA-21 through a highly
conserved enhancer. Blood. 110:1330–1333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu HY, Li KP, Wang XJ, Liu Y, Lu ZG, Dong
RH, Guo HB and Zhang MX: Set9, NF-kappaB and microRNA-21 mediate
berberine-induced apoptosis of human multiple myeloma cells. Acta
Pharmacol Sin. 34:157–166. 2013. View Article : Google Scholar
|
|
15
|
Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu
W, Yang K, He X and Chen S: MicroRNA-21 acts as an oncomir through
multiple targets in human hepatocellular carcinoma. J Hepatol.
53:98–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu J, Wu C, Che X, Wang L, Yu D, Zhang T,
Huang L, Li H, Tan W, Wang C and Lin D: Circulating microRNAs,
miR-21, miR-122 and miR-223, in patients with hepatocellular
carcinoma or chronic hepatitis. Mol Carcinog. 50:136–142. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pichiorri F, Suh SS, Ladetto M, Kuehl M,
Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP,
Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI
and Croce CM: MicroRNAs regulate critical genes associated with
multiple myeloma pathogenesis. Proc Natl Acad Sci USA.
105:12885–12890. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cabrita MA and Christofori G: Sprouty
proteins, masterminds of receptor tyrosine kinase signaling.
Angiogenesis. 11:53–62. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lito P, Mets BD, Kleff S, O’Reilly S,
Maher VM and McCormick JJ: Evidence that sprouty 2 is necessary for
sarcoma formation by H-Ras oncogene-transformed human fibroblasts.
J Biol Chem. 283:2002–2009. 2008. View Article : Google Scholar
|
|
20
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar
|
|
21
|
Yedjou CG and Tchounwou PB: In-vitor
cytotoxic and genotoxic effects of arsenic trioxide on human
leukemia (HL-60) cells using the MTT and alkaline single cell
gelelectrophoresis (Comet) assays. Mol Cell Biochem. 301:123–130.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng YH, Wu CL, Tsao CJ, Chang JG, Lu PJ,
Yeh KT, Uen YH, Lee JC and Shiau AL: Deregulated expression of
sprouty2 and microRNA-21 in human colon cancer: Correlation with
the clinical stage of the disease. Cancer Biol Ther. 11:111–121.
2011. View Article : Google Scholar
|
|
23
|
Wang X, Li C, Ju S, Wang Y, Wang H and
Zhong R: Myeloma cell adhesion to bone marrow stromal cells confers
drug resistance by microRNA-21 up-regulation. Leuk Lymphoma.
52:1991–1998. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiong Q, Zhong Q, Zhang J, Yang M, Li C,
Zheng P, Bi LJ and Ge F: Identification of novel miR-21 target
proteins in multiplemyeloma cells by quantitative proteomics. J
Proteome Res. 11:2078–2090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shah AA, Leidinger P, Blin N and Meese E:
miRNA: small molecules as potential novel biomarkers in cancer.
Curr Med Chem. 17:4427–4432. 2010. View Article : Google Scholar : PubMed/NCBI
|
